Updated Follow-up and Results of Subsequent Therapy in the Phase III VISTA Trial: Bortezomib Plus Melphalan-Prednisone Versus Melphalan-Prednisone in Newly Diagnosed Multiple Myeloma

被引：0

作者：

Miguel, Jesus F. San ^{[1
]}

Schlag, Rudolf ^{[2
]}

Khuageva, Nuriet K. ^{[3
]}

Dimopoulos, Meletios A. ^{[4
]}

Shpilberg, Ofer ^{[5
]}

Kropff, Martin H. ^{[6
]}

Spicka, Ivan ^{[7
]}

Petrucci, Maria Teresa ^{[8
]}

Palumbo, Antonio ^{[9
]}

Samoilova, Olga S. ^{[10
]}

Dmoszynska, Anna ^{[11
]}

Abdulkadyrov, Kudrat M. ^{[12
]}

Schots, Rik ^{[13
]}

Jiang, Bin ^{[14
]}

Mateos, Maria-Victoria ^{[15
]}

Anderson, Kenneth C. ^{[16
]}

Esseltine, Dixie-Lee ^{[17
]}

Liu, Kevin ^{[18
]}

Cakana, Andrew ^{[19
]}

van de Velde, Helgi ^{[19
]}

Richardson, Paul

机构：

[1] USAL, CSIC, IBMCC, CIC,Hosp Univ Salamanca, Salamanca, Spain

[2] Praxis Hematol & Oncol, Wurzburg, Germany

[3] SP Botkin Moscow City Clin Hosp, Dept Hematol, Moscow, Russia

[4] Univ Athens, Sch Med, Dept Clin Therapeut, GR-11527 Athens, Greece

[5] Rabin Med Ctr, Petah Tiqwa, Israel

[6] Univ Munster, Munster, Germany

[7] Charles Univ Praha, Dept Int Med 1, Prague, Czech Republic

[8] Univ Roma La Sapienza, Rome, Italy

[9] Univ Turin, Div Ematol, AOU San Giovanni Battista, Turin, Italy

[10] Nizhnii Novgorod Reg Clin Hosp, Nizhnii Novgorod, Russia

[11] Med Univ Lublin, Lublin, Poland

[12] St Petersburg Clin Res Inst Hematol & Transfusiol, St Petersburg, Russia

[13] Belgian Hematol Soc, Myeloma Study Grp, Brussels, Belgium

[14] Peking Univ, Peoples Hosp, Beijing, Peoples R China

[15] Hosp Univ Salamanca, Salamanca, Spain

[16] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Dis Ctr, Boston, MA 02115 USA

[17] Takeda Oncol Co, Millennium Pharmaceut, Cambridge, MA USA

[18] Johnson & Johnson Pharmaceut Res & Dev, Raritan, NJ USA

[19] Johnson & Johnson Pharmaceut Res & Dev, Dept Clin R&D Oncol, Beerse, Belgium

来源：

BLOOD | 2008年 / 112卷 / 11期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：242 / 242

页数：1

共 50 条

[21] A Prospective, Randomized, Phase III Study of Bortezomib, Melphalan, Prednisone and Thalidomide (VMPT) Versus Bortezomib, Melphalan and Prednisone (VMP) in Elderly Newly Diagnosed Myeloma Patients
Palumbo, Antonio
Bringhen, Sara
Rossi, Davide
Magarotto, Valeria
Di Raimondo, Francesco
Ria, Roberto
Offidani, Massimo
Nozzoli, Chiara
Patriarca, Francesca
Callea, Vincenzo
Benevolo, Giulia
Marasca, Roberto
Guglielmelli, Tommasina
Rizzo, Manuela
Grasso, Mariella
Petrucci, Maria Teresa
Omede, Paola
Gaidano, Gianluca
Boccadoro, Mario
BLOOD, 2008, 112 (11) : 243 - 243
[22] BORTEZOMIB, MELPHALAN, PREDNISONE AND THALIDOMIDE (VMPT) VERSUS BORTEZOMIB, MELPHALAN AND PREDNISONE (VMP) IN ELDERLY NEWLY DIAGNOSED MYELOMA PATIENTS: A PROSPECTIVE, RANDOMIZED, PHASE III STUDY
Palumbo, A.
Bringhen, S.
Rossi, D.
Ria, R.
Berretta, S.
Offidani, M.
Patriarca, F.
Nozzoli, C.
Levi, A.
Guglielmelli, T.
Benevolo, G.
Callea, V.
Liberati, A. M.
Crippa, C.
Di Renzo, N.
Catalano, L.
De Sabbata, G.
Rizzi, R.
Feo, C.
Mazza, R.
Farina, G.
Spadano, A.
Pisani, F.
Podda, L.
Aitoro, G.
Magarotto, V.
Astolfi, M.
Di Raimondo, F.
Gaidano, G.
Boccadoro, M.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 190 - 191
[23] Melphalan, prednisone and thalidomide (MPT) versus melphalan and prednisone (MP) in newly diagnosed myeloma: Results of a prospective, randomized phase III study
Bringhen, S.
Liberati, A. M.
Caravita, T.
Falcone, A.
Dore, F.
Carubelli, A.
Elice, F.
Griso, L.
Foli, C.
Darbesio, A.
Baraldi, A.
Cellini, C.
Annino, L.
Piro, E.
Magarotto, V
Avonto, I
Musto, P.
Boccadoro, M.
Palumbo, A.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 135 - 136
[24] Daratumumab, Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in TransplantIneligible Patients with Newly Diagnosed Multiple Myeloma: Pooled Analysis of Octans and Alcyone
Hou, Jian
Fu, Weijun
Bang, Soo-Mee
Huang, Honghui
Kim, Kihyun
Li, Wei
An, Gang
Lee, Je-Jung
Cai, Zhen
Jin, Jie
Wang, Yafei
Chim, C. S.
Rodriguez-Otero, Paula
Dimopoulos, Meletios A.
Fujisaki, Tomoaki
Lee, Jae Hoon
Wroblewski, Susan
Carson, Robin
Qi, Ming
Wang, Jianping
Song, Yang
Bin Jia
Yang, Xue
Liu, Wenyu
Li, Yunan
Zhang, Renyi
Wang, Jianxiang
BLOOD, 2021, 138
[25] MULTIPLE-MYELOMA - RESULTS FROM TREATMENT OF 50 PATIENTS RECEIVING MELPHALAN-PREDNISONE-PROCARBAZINE (MPP) OR MELPHALAN-PREDNISONE (MP)
LIRA, P
WALKER, B
GREBE, G
REVISTA MEDICA DE CHILE, 1985, 113 (06) : 8 - 8
[26] CMP-CARFILZOMIB (CFZ) PLUS MELPHALAN-PREDNISONE (MP)-IN ELDERLY PATIENTS (PTS) WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): RESULTS OF A PHASE (PH) I/II TRIAL
Moreau, P.
Kolb, B.
Hulin, C.
Caillot, D.
Benboubker, L.
Tiab, M.
Touzeau, C.
Leleu, X.
Roussel, M.
Chaleteix, C.
Attal, M.
Facon, T.
HAEMATOLOGICA, 2013, 98 : 97 - 97
[27] Sustained Health-Related Quality of Life (HRQoL) Improvement in Newly Diagnosed Multiple Myeloma Patients Treated with Bortezomib/Melphalan/Prednisone Versus Melphalan/Prednisone: Results From the VISTA Trial.
Dhawan, Ravinder
Robinson, Don, Jr.
Meunier, Juliette
Regnault, Antoine
Rosa, Kathleen
Cakana, Andrew Z.
van de Velde, Helgi
Richardson, Paul G.
San Miguel, Jesus F.
BLOOD, 2009, 114 (22) : 747 - 747
[28] Cost-effectiveness analysis of daratumumab plus bortezomib, melphalan and prednisone versus bortezomib, melphalan and prednisone in patients with newly diagnosed multiple myeloma ineligible for stem cell transplantation
Xie, Dan
Zhang, Peng-Fei
BMJ OPEN, 2025, 15 (02):
[29] A randomized trial with melphalan and prednisone versus melphalan and prednisone plus thalidomide in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplant
Sacchi, Stefano
Marcheselli, Raffaella
Lazzaro, Antonio
Morabito, Fortunato
Fragasso, Alberto
Di Renzo, Nicola
Balleari, Enrico
Neri, Santo
Quarta, Giovanni
Ferrara, Raimondo
Vigliotti, Maria Luigia
Polimeno, Giuseppe
Musto, Pellegrino
Consoli, Ugo
Zoboli, Alessandra
Buda, Gabriele
Pastorini, Alessandro
Masini, Luciano
LEUKEMIA & LYMPHOMA, 2011, 52 (10) : 1942 - 1948
[30] Phase 3 Study (CLARION) of Carfilzomib, Melphalan, Prednisone (KMP) v Bortezomib, Melphalan, Prednisone (VMP) in Newly Diagnosed Multiple Myeloma (NDMM)
Facon, Thierry
Lee, Jae Hoon
Moreau, Philippe
Niesvizky, Ruben
Dimopoulos, Meletios Athanasios
Hajek, Roman
Osman, Muhtarjan
Aggarwal, Sanjay
Klippel, Zandra
Miguel, Jesus San
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (01): : E26 - E27

← 1 2 3 4 5 →